Cambridge Cognition Holdings Plc (COG)
London Exchange · UK · prices in GBX · close of 23 Oct 2026
Key indicators
| Last close | GBX 27.00 |
|---|---|
| 52-week range | 26.60 – 45.00 |
| Return, 1 month / 3 months | −3.6% / −16.9% |
| Return, 1 year / 3 years | −20.6% / −61.4% |
| Trend | Below its 200-day average |
| RSI (14) | 24 |
| Volatility (1 year) | 30.4% |
| Worst drawdown (1 year) | -37.9% |
| Average daily value traded | 0.69M GBX |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Cambridge Cognition Holdings provides computerised cognitive assessment software and related services. Its tests, developed from academic research in Cambridge, measure memory, attention and other thinking skills, and are used by pharmaceutical companies running clinical trials, by academic researchers and by healthcare organisations assessing patients. The company is based in Cambridge in the United Kingdom, and its customers include drug developers and research institutions in several countries who need reliable, repeatable ways to measure cognitive function.
Cambridge Cognition Holdings Plc trades under the code COG on the London Exchange in UK, with its price quoted in pence sterling (GBX). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Cambridge Cognition Holdings Plc (COG) trades on the London Exchange in UK. It last closed at GBX 27.00 on 23 October 2026.
Its price-based Market X-Ray is 31 out of 100 (a weak price profile), ranking 3,043 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 20.6% and over the last three months it fell 16.9%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 17 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -20.7% | ||
| From 52-week high | -37.9% | ||
| Momentum | 18 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -16.9% | ||
| 6-month return | -26.0% | ||
| 12-month return, skipping the last month | -17.6% | ||
| Stability (higher is calmer) | 48 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 30.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -37.9% | ||
| Liquidity | 49 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.69M GBX | ||
| Zero-volume days | 1.7% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −3.6% |
|---|---|
| 1 month | −3.6% |
| 3 months | −16.9% |
| 6 months | −26.0% |
| 1 year | −20.6% |
| 3 years | −61.4% |
| 5 years | −80.3% |
Signals
| 50-day / 200-day average | 29.11 / 34.05 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.39 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.